Release of cytokines from human umbilical vein endothelial cells treated with platinum compounds in vitro

Japanese Journal of Cancer Research

Volumn 89, Issue 7, 1998, Pages 757-767

  Shi, Yucheng ^a   Inoue, Shoichi ^a   Shinozaki, Reiko ^a   Fukue, Kaoru ^a   Kougo, Tohru ^b  

^a HOKKAIDO UNIVERSITY   (Japan)

^b Sapporo Maternity Women's Hospital   (Japan)

Author keywords

Cytokine; Endothelial cell; Hydrogen peroxide; Platinum compound

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROGEN PEROXIDE; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; PLATINUM DERIVATIVE; RHODAMINE 123;

ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONFOCAL LASER MICROSCOPY; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; TIME; UMBILICAL VEIN;

EID: 0031693792     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1998.tb03281.x     Document Type: Article

References (49)

1. Shepro, D. and Morel, N. M. L. Pericyte physiology. FASEB J., 7, 1031-1038 (1993).
2. McMillen, M. A., Huribal, M. and Sumpio, B. Common pathway of endothelial-leukocyte interaction in shock, ischemia, and reperfusion. Am. J. Surg., 166, 557-562 (1993).
3. Ley, K. Molecular mechanisms of leukocyte recruitment in the inflammatory process. Cardiovasc. Res., 32, 733-742 (1996).
4. Risau, W. Differentiation of endothelium. FASEB J., 9, 926-933 (1995).
5. Pomerat, C. M. and Slick, W. C. Isolation and growth of endothelial cells in tissue culture. Nature, 198, 859-861 (1963).
6. Fryer, D. G., Birnbaum, G. and Luttrell, C. N. Human endothelium in cell culture. J. Atheroscler. Res., 6, 151-163 (1966).
7. Yoshizumi, M., Kurihara, H., Morita, T., Yamashita, T., Oh-hashi, Y., Sugiyama, T., Takaku, F., Yanagisawa, M., Masaki, T. and Yazaki, Y. Interleukin 1 increases the production of endothelin-1 by cultured endothelial cells. Biochem. Biophys. Res. Commun., 166, 324-329 (1990).
8. Yonemura, Y., Ku, H., Hirayama, F., Souza, L. M. and Ogawa, M. Interleukin 3 or interleukin 1 abrogates the reconstituting ability of hematopoietic stem cells. Proc. Natl. Acad. Sci. USA, 93, 4040-4044 (1996).
9. Shalaby, M. R., Waage, A. and Espevik, T. Cytokine regulation of interleukin 6 production by human endothelial cells. Cell. Imnumol., 121, 372-382 (1989).
10. Sironi, M., Breviario, F., Proserpio, P., Biondi, A., Vecchi, A., Van Damme, J., Dejana, E. and Mantovani, A. IL-1 stimulates IL-6 production in endothelial cells. J. Immunol., 142, 549-553 (1989).
11. Ikebuchi, K., Wong, G. G., Clark, S. C., Ihle, J. N., Hirai, Y. and Ogawa, M. Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc. Natl. Acad. Sci. USA, 84, 9035-9039 (1987).
12. Morsey, M. A., Popowych, Y., Kowalski, J., Gerlach, G., Godson, D. and Campos, M. Molecular cloning and expression of bovine interleukin 8. Microb. Pathog., 20, 203-212 (1996).
13. Strieter, R. M., Kunkel, S. L., Schowell, H. J. and Marks, R. M. Monokine-induced gene expression of a human endothelial cell derived neutrophil chemotactic factor. Biochem. Biophys. Res. Commun., 156, 1340-1345 (1988).
14. Gimbrone, M. A., Jr., Obin, M. S., Brock, A. F., Luis, E. A., Hass, P. E., Hebert, C. A., Yip, Y. K., Leung, D. W., Lowe, D. G., Kohr, W. J., Darbonne, W. C., Bechtol, K. B. and Baker, J. B. Endothelial interleukin-8: a novel inhibitor of leukocyte-endothelial interactions. Science, 246, 1601-1603 (1989).
15. Colditz, I., Zwahlen, R., Dewald, B. and Baggiolini, M. In vivo inflammatory activity of neutrophil-activating factor, a novel chemotactic peptide derived from human monocytes. Am. J. Pathol., 134, 755-760 (1989).
16. O'Flaherty, J. T., Showell, H. J. and Ward, P. A. Neutropenia induced by systemic infusion of chemotactic factors. J. Immunol., 118, 1586-1589 (1977).
17. Obin, M. S., Kiely, J. M., Hebert, C., Baker, J. and Gimbrone, M. A., Jr. Endothelial interleukin-8: a novel inhibitor of leukocyte adhesion. FASEB J., 4, A625 (1977).
18. Donahue, R. E., Emerson, S. G., Wang, E. A., Wong, G. G., Clark, S. C. and Nathan, D. G. Demonstration of burst-promoting activity of recombinant human GM-CSF on circulating erythroid progenitors using an assay involving the delayed addition of erythropoietin. Blood, 66, 1479-1481 (1985).
19. Emerson, S. G., Sieff, C. A., Wang, E. A., Wong, G. G., Clark, S. C. and Nathan, D. G. Purification of fetal hematopoietic progenitors and demonstration of recombinant multipotential colony-stimulating activity. J. Clin. Invest., 76, 1286-1290 (1985).
20. Sieff, C. A., Emerson, S. G., Donahue, R. E., Nathan, D. G., Wang, E. A., Wong, G. G. and Clark, S. C. Human recombinant granulocyte-macrophage colony-stimulating factor: a multilineage hematopoietin. Science, 230, 1171-1173 (1985).
21. Sieff, C. A., Emerson, S. G., Mutson, A., Gesner, T. G. and Nathan, D. G. Dependence of highly enriched human bone marrow progenitors on hemopoietic growth factors and their response to recombinant erythropoietin. J. Clin. Invest., 77, 74-81 (1986).
22. Baker, F. L., Broxmeyer, H. E. and Galbraith, P. R. Control of granulopoiesis in man. III. Inhibition of colony formation by dense leukocytes. J. Cell. Physiol., 86, 337-342 (1975).
23. Weisbart, R. H., Golde, D. W., Clark, S. C., Wong, G. G. and Gasson, J. C. Human granulocyte-macrophage colony-stimulating factor is a neutrophil activator. Nature, 314, 361-363 (1985).
24. Jaswon, M. S., Khwaja, A., Roberts, P. J., Jones, H. M. and Linch, D. C. The effects of rhGM-CSF on the neutrophil respiratory burst when studied in whole blood. Br. J. Haematol., 75, 181-187 (1990).
25. Taylor, S. G., IV Head and neck cancer. In "Cancer Chemotherapy," ed. H. M. Pinedo, pp. 291-306 (1979). Elsevier, Amsterdam.
26. Bradner, W. T., Rose, W. C. and Huftalen, J. B. Antitumor activity of platinum analogs. In "Cisplatin: Current Status and New Developments," ed. A. W. Prestayko, S. T. Crooke and S. K. Carier, pp. 171-182 (1980). Academic Press, New York.
27. Calvert, A. H., Harland, S. J., Newell, D. R., Siddik, Z. H., Jones, A. C., McElwain, T. J., Raju, S., Wiltshaw, E., Smith, I. E., Baker, J. M., Peckham, M. J. and Harrap, K. R. Early clinical studies with cis-diammine-1,1 -cyclobutane dicarboxylato platinum II. Cancer Chemother. Pharmacol., 9, 140-147 (1982).
28. Rozencweig, M., Nicaise, C., Beer, M., Crespeigne, N., Van Rijmenant, M., Lenaz, L. and Kenis, Y. Phase I study of carboplatin given on a five-day intravenous schedule. J. Clin. Oncol., 1, 621-626 (1983).
29. Van Echo, D. A., Egorin, M. J., Whitacre, M. Y., Olman, E. A. and Aisner, J. Phase I clinical and pharmacologic trial of carboplatin daily for 5 days. Cancer Treat. Rep., 68, 1103-1114 (1984).
30. Saito, T., Manabe, Y. and Saito, H. Ototoxicity of the new platinum anticancer agent TRK-710 in comparison with cisplatin. ORL (Basel), 57, 250-255 (1996).
31. Hoagland, H. C. Hematologic complications of cancer chemotherapy. In "The Chemotherapy Source Book," ed. M. C. Perry, pp. 498-507 (1992). Williams & Wilkins, Baltimore.
32. Nicosia, R. F., Villaschi, S. and Smith, M. Isolation and characterization of vasoformative endothelial cells from the rat aorta. In Vitro Cell Dev. Biol. Anim., 30A, 394-399 (1994).
33. Ratain, M. J. and Sehisky, R. L. Principles of pharmacology and phamacokinetics. In "The Chemotherapy Source Book," ed. M. C. Pery, pp. 22-35 (1992). Williams & Wilkins, Baltimore.
34. Yamamoto, N., Tamura, T., Maeda, M., Ando, M., Shinkai, T., Eguchi, K., Ohe, Y., Oshita. F., Shiraishi, J. T., Katsumata, N. and Saijo, N. The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal organ function. Cancer Chemother. Pharmacol., 36, 102-106 (1995).
35. Oguri, S., Sakakibara, T., Mase, H., Shimizu, T., Ishikawa, K., Kimura, K. and Smyth, R. D. Clinical pharmacokinetics of carboplatin. J. Clin. Pharmacol., 28, 208-215 (1988).
36. Yuan, L., Inoue, S., Saito, Y. and Nakajima, O. An evaluation of the effects of cytokines on intracellular oxidative production in normal neutrophils by flow cytometry. Exp. Cell Res., 209, 375-381 (1993).
37. Inoue, S., Mizuno, S., Ito, M. and Ohnuma T. Flow cytometric analyses of the characteristics of tumor cells treated with two platinum compounds: 1,1-cyclobutanedicarboxylato(2-aminomethylpyrrolidine)platinum(II) and cisplatin. Jpn. J. Cancer Res., 83, 1231-1240 (1992).
38. Booyse, F. M., Sedlak, B. J. and Rafelson, M. E. Culture of arterial endothelial cells: characterization and growth of bovine aortic cells. Thromb. Diath. Haemorrh., 34, 825-839 (1975).
39. Baggiolini, M., Walz, A. and Kunkel, S. L. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J. Clin. Invest., 84, 1045-1049 (1989).
40. Nakata, T., Suzuki, K., Fujii, J., Ishikawa, M. and Taniguchi N. Induction and release of manganese superoxide dismutase from mitochondria of human umbilical vein endothelial cells by tumor necrosis factor-α and interleukin-1α. Int. J. Cancer, 55, 646-650 (1993).
41. Taniguchi, N. Clinical significances of superoxide dismutases: changes in aging, diabetes, ischemia, and cancer. In "Advances in Clinical Chemistry," ed. E. H. Spiegel, Vol. 29, pp. 1-59 (1992). Academic Press, San Diego.
42. Ono, M., Kohda, H., Kawaguchi, T., Ohhira, M., Sekiya, C., Namiki, M., Takeyasu, A. and Taniguchi, N. Induction of Mn-superoxide dismutase by tumor necrosis factor, interleukin-1 and interleukin-6 in human hepatoma cells. Biochem. Biophys. Res. Commun., 182, 1100-1107 (1992).
43. Prajda, N., Kralovanszky, J., Gal, F., Kiss, F. and Kerpel Fronius, S. Evaluation of side effects of platinum complexes (CDDP, CBDCA. CHIP) on bone marrow. In Vivo, 3, 267-270 (1989).
44. Keating, M. J., Estey, E. and Kantarjian, H. Acute leukemia. In "Cancer: Principles and Practice of Oncology," Vol. 2, 4th Ed., ed. V. T. DcVita, Jr., S. Hellman and S. A. Rosenberg, pp. 1938-1964 (1993). Lippincott, Philadelphia.
45. Mochizuki, D. Y., Eisenman, J. R., Conlan, P. J., Larsen, A. D. and Tushinski, R. J. Interleukin 1 regulates hematopoietic activity, a role previously ascribed to hemopoietin 1. Proc. Natl. Acad. Sci. USA, 84, 5267-5370 (1987).
46. Bruno, E. and Hoffman, R. Effect of interleukin-6 on in vitro human megakaryocytopoiesis: its interaction with other cytokines. Exp. Hematol., 17, 1038-1042 (1989).
47. Weisdorf, D., Katsanis, E., Verfaillie, C., Ramsay, N. K. C., Haake, R., Garrison, L. and Blazar, B. R. Interleukin-1 alpha administered after autologous transplantation: a phase I/II clinical trial. Blood, 84, 2044-2049 (1994).
48. Triozzi, P. L., Kim, J. A., Martin, E. W., Youg, D. C., Benzies, T. and Villasmil, P. A. Phase 1 trial of escalating doses of interleukin-1β in combination with a fixed dose of interkeukin-2. J. Clin. Oncol., 13, 482-489 (1995).
49. Engerman, R. L., Pfaffenbach, D. and Davis, M. D. Cell turnover of capillaries. Lab. Invest., 17, 738-743 (1967).